AU2013283318B2 - Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders - Google Patents
Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders Download PDFInfo
- Publication number
- AU2013283318B2 AU2013283318B2 AU2013283318A AU2013283318A AU2013283318B2 AU 2013283318 B2 AU2013283318 B2 AU 2013283318B2 AU 2013283318 A AU2013283318 A AU 2013283318A AU 2013283318 A AU2013283318 A AU 2013283318A AU 2013283318 B2 AU2013283318 B2 AU 2013283318B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- group
- independently selected
- nhco
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018201275A AU2018201275A1 (en) | 2012-06-27 | 2018-02-22 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmune inflammation and CNS disorders |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664936P | 2012-06-27 | 2012-06-27 | |
| US61/664,936 | 2012-06-27 | ||
| EP12174669 | 2012-07-02 | ||
| EP12174669.7 | 2012-07-02 | ||
| PCT/EP2013/063537 WO2014001464A1 (en) | 2012-06-27 | 2013-06-27 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018201275A Division AU2018201275A1 (en) | 2012-06-27 | 2018-02-22 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmune inflammation and CNS disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013283318A1 AU2013283318A1 (en) | 2015-01-22 |
| AU2013283318B2 true AU2013283318B2 (en) | 2017-11-23 |
Family
ID=49782305
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013283318A Ceased AU2013283318B2 (en) | 2012-06-27 | 2013-06-27 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders |
| AU2018201275A Abandoned AU2018201275A1 (en) | 2012-06-27 | 2018-02-22 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmune inflammation and CNS disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018201275A Abandoned AU2018201275A1 (en) | 2012-06-27 | 2018-02-22 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmune inflammation and CNS disorders |
Country Status (19)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX350418B (es) * | 2012-06-27 | 2017-09-06 | 4Sc Discovery Gmbh | Inhibidores de bifluorodioxalano-amino-bencimidazol quinasa para el tratamiento de cáncer, inflamación autoinmune y trastornos del sistema nervioso central. |
| WO2015143161A1 (en) | 2014-03-20 | 2015-09-24 | Capella Therapeutics, Inc. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
| RU2741914C2 (ru) | 2014-03-20 | 2021-01-29 | Капелла Терапьютикс, Инк. | Производные бензимидазола как ингибиторы тирозинкиназ erbb для лечения рака |
| JP6633618B2 (ja) | 2014-08-21 | 2020-01-22 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 強力なｒｏｃｋ阻害剤としてのタイドバックのベンズアミド誘導体 |
| WO2017013210A1 (en) * | 2015-07-21 | 2017-01-26 | 4Sc Ag | Treatment and prevention of viral diseases with 2,3-dihydrobenzofuran-5-yl compounds |
| US10590108B2 (en) | 2015-09-23 | 2020-03-17 | Capella Therapeutics, Inc. | Benzimidazoles for use in the treatment of cancer and inflammatory diseases |
| SI3440076T1 (sl) * | 2016-04-07 | 2022-09-30 | Glaxosmithkline Intellectual Property Development Limited | Heterociklični amidi uporabni kot proteinski modulatorji |
| EP3700536A4 (en) | 2017-10-27 | 2021-11-17 | Shanghai Yao Yuan Biotechnology Co., Ltd. | COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNE RESPONSE BY ACTIVATION OF KINASE ALPHA 1 PROTEIN |
| MX2021002949A (es) | 2018-09-13 | 2021-05-12 | Bayer Ag | Derivados heterociclicos como plaguicidas. |
| CN109020990A (zh) * | 2018-09-20 | 2018-12-18 | 广西壮族自治区药用植物园 | 苯基苯并呋喃化合物、及其制备方法、组合物和医药用途 |
| KR102119150B1 (ko) * | 2018-10-23 | 2020-06-04 | 한국원자력의학원 | N-1h-벤지미다졸-2-일-3-(1h-피롤-1-일) 벤자미드를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물 |
| EP3643713A1 (en) * | 2018-10-23 | 2020-04-29 | iOmx Therapeutics AG | Heterocyclic kinase inhibitors and uses thereof |
| WO2020132582A1 (en) * | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting agonists and uses thereof |
| KR20230031285A (ko) | 2020-06-26 | 2023-03-07 | 라퀄리아 파마 인코포레이티드 | 레티노이드와 암 치료제의 병용 요법이 효과적인 암 환자를 선별하는 방법 및 레티노이드와 암 치료제의 병용 의약 |
| CN116942819A (zh) * | 2023-04-24 | 2023-10-27 | 珠海市人民医院 | 微管相关丝氨酸/苏氨酸样激酶抑制剂在制备治疗肿瘤的药物中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006130673A1 (en) * | 2005-05-31 | 2006-12-07 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4167569A (en) | 1976-12-09 | 1979-09-11 | Imperial Chemical Industries Limited | Pyrimido[1,2-a ]benzimidazole derivatives |
| JP4445262B2 (ja) | 2001-10-09 | 2010-04-07 | アムジェン インコーポレイテッド | 抗炎症剤としてのイミダゾール誘導体 |
| EP1388341A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| US7338956B2 (en) | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| JO2724B1 (en) | 2004-08-19 | 2013-09-15 | افينتس فارماسوتيكالز انك | 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors |
| US8338594B2 (en) | 2005-12-02 | 2012-12-25 | Bayer Healthcare Llc | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase |
| PE20080403A1 (es) * | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| FR2918061B1 (fr) | 2007-06-28 | 2010-10-22 | Sanofi Aventis | Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique. |
| WO2009047163A1 (en) | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| US9062076B2 (en) * | 2009-10-22 | 2015-06-23 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
| MX350418B (es) * | 2012-06-27 | 2017-09-06 | 4Sc Discovery Gmbh | Inhibidores de bifluorodioxalano-amino-bencimidazol quinasa para el tratamiento de cáncer, inflamación autoinmune y trastornos del sistema nervioso central. |
-
2013
- 2013-06-27 MX MX2014015938A patent/MX350418B/es active IP Right Grant
- 2013-06-27 UA UAA201500560A patent/UA116541C2/uk unknown
- 2013-06-27 NZ NZ702618A patent/NZ702618A/en not_active IP Right Cessation
- 2013-06-27 EA EA201500050A patent/EA029718B1/ru not_active IP Right Cessation
- 2013-06-27 MY MYPI2014003556A patent/MY167785A/en unknown
- 2013-06-27 US US14/411,795 patent/US9580438B2/en active Active
- 2013-06-27 IN IN2562MUN2014 patent/IN2014MN02562A/en unknown
- 2013-06-27 CA CA2877589A patent/CA2877589C/en not_active Expired - Fee Related
- 2013-06-27 JP JP2015519098A patent/JP6272846B2/ja not_active Expired - Fee Related
- 2013-06-27 BR BR112014032581A patent/BR112014032581A8/pt not_active Application Discontinuation
- 2013-06-27 EP EP13731822.6A patent/EP2867237A1/en not_active Withdrawn
- 2013-06-27 KR KR1020157001782A patent/KR102155559B1/ko active IP Right Grant
- 2013-06-27 CN CN201380034461.4A patent/CN104540831B/zh not_active Expired - Fee Related
- 2013-06-27 SG SG11201408617PA patent/SG11201408617PA/en unknown
- 2013-06-27 WO PCT/EP2013/063537 patent/WO2014001464A1/en active Application Filing
- 2013-06-27 AU AU2013283318A patent/AU2013283318B2/en not_active Ceased
-
2014
- 2014-12-12 ZA ZA2014/09194A patent/ZA201409194B/en unknown
- 2014-12-25 IL IL236463A patent/IL236463A0/en unknown
-
2015
- 2015-05-26 HK HK15105006.4A patent/HK1204474A1/xx unknown
-
2017
- 2017-02-27 US US15/443,180 patent/US20170240556A1/en not_active Abandoned
-
2018
- 2018-01-04 JP JP2018000285A patent/JP2018076360A/ja active Pending
- 2018-02-22 AU AU2018201275A patent/AU2018201275A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006130673A1 (en) * | 2005-05-31 | 2006-12-07 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
Non-Patent Citations (1)
| Title |
|---|
| BISCHOF, J. et al: Amino Acids; The Forum for Amino Acid and Protein Research, 2012, 43(4), pages 1577-1591 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102155559B1 (ko) | 2020-09-15 |
| MX350418B (es) | 2017-09-06 |
| HK1204474A1 (en) | 2015-11-20 |
| EA201500050A1 (ru) | 2015-09-30 |
| ZA201409194B (en) | 2017-08-30 |
| CN104540831B (zh) | 2017-11-07 |
| US20170240556A1 (en) | 2017-08-24 |
| CA2877589A1 (en) | 2014-01-03 |
| JP2015525742A (ja) | 2015-09-07 |
| AU2013283318A1 (en) | 2015-01-22 |
| JP2018076360A (ja) | 2018-05-17 |
| WO2014001464A1 (en) | 2014-01-03 |
| MX2014015938A (es) | 2015-07-21 |
| US9580438B2 (en) | 2017-02-28 |
| CN104540831A (zh) | 2015-04-22 |
| MY167785A (en) | 2018-09-25 |
| EP2867237A1 (en) | 2015-05-06 |
| JP6272846B2 (ja) | 2018-01-31 |
| US20150158878A1 (en) | 2015-06-11 |
| IL236463A0 (en) | 2015-02-26 |
| KR20150037877A (ko) | 2015-04-08 |
| BR112014032581A8 (pt) | 2018-08-14 |
| BR112014032581A2 (pt) | 2017-06-27 |
| UA116541C2 (uk) | 2018-04-10 |
| SG11201408617PA (en) | 2015-01-29 |
| IN2014MN02562A (US07094801-20060822-C00173.png) | 2015-07-24 |
| NZ702618A (en) | 2016-12-23 |
| EA029718B1 (ru) | 2018-05-31 |
| CA2877589C (en) | 2019-11-26 |
| AU2018201275A1 (en) | 2018-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013283318B2 (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders | |
| US11773110B2 (en) | Heterocycle amines and uses thereof | |
| CA2915566C (en) | 2,3-dihydrobenzofuran-5-yl compounds as dyrk kinase inhibitors | |
| JP6759514B2 (ja) | ブロモドメインに対して活性な化合物 | |
| RU2559895C2 (ru) | Азотосодержащие производные гетероарилов | |
| CA2978823A1 (en) | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | |
| AU2017444054B2 (en) | Class of pyrimidine derivative kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| HB | Alteration of name in register |
Owner name: 4SC AG Free format text: FORMER NAME(S): 4SC DISCOVERY GMBH |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |